Skip to main content

Table 1 Patient cohorts and characteristics

From: Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy

 

Cohort 1

TCGA

No. of patients

%

No. of patients

%

No. of patients

55

452

Sex

 Male

37

67.3

290

64.2

 Female

18

32.7

162

35.8

Age median (range)

70 (32–84)

61 (29–90)

Stage

 1

24

43.6

221

48.9

 2

3

5.5

44

9.7

 3

14

25.5

116

25.7

 4

14

25.5

69

15.3

 NA

2

0.4

Primary tumor

 1

26

47.3

227

50.2

 2

4

7.3

56

12.4

 3

24

43.6

164

36.3

 4

1

1.8

5

1.1

N

 0

46

83.6

203

44.9

 1/2

7

12.7

11

2.4

 X

2

3.6

238

52.7

M

 0

42

76.4

377

83.4

 1

13

23.6

68

15.0

 X

7

1.5

G

 1

8

14.5

10

2.2

 2

38

69.1

188

41.6

 3/4

9

16.4

251

55.5

 X

1

0.2

 NA

2

0.4

Median follow-up time [years] (range)

2.9 (0–10.1)

3.5 (0–12.4)

Overall survivala [years]

 Deceased

28

50.9

145

32.1

 Alive

26

47.3

307

67.9

  1. Abbreviations: N regional lymph nodes, M distant metastasis, G grading, NA not available
  2. aInformation on overall survival was not available for all patients